Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: Comparison of oral and continuous iv administration of 5-fluorouracil

A. Y. Bedikian, R. Staab, Robert B Livingston, M. Valdivieso, M. A. Burgess, G. P. Bodey

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Forty-six patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds. The overall response rate in 37 patients with measurable disease was 25%. The response was greater in patients who had had no prior treatment (seven of 20 versus two of 17) and in patients treated with FCC-CIF (six of 19 versus three of 18). Among patients receiving FCC-CIF, response was also greater in those who had received no prior therapy (five of nine versus one of ten). The overall median survival was 7.5 months, regardless of the route of administration of 5-FU. Further investigations are indicated to study the efficacy of 5-FU administered by continuous iv infusion in combination with other agents in patients who have had no prior treatment.

Original languageEnglish (US)
Pages (from-to)1603-1605
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number10
StatePublished - 1978
Externally publishedYes

Fingerprint

Lomustine
Fluorouracil
Cyclophosphamide
Colorectal Neoplasms
Drug Therapy
Proxy
Therapeutics
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU : Comparison of oral and continuous iv administration of 5-fluorouracil. / Bedikian, A. Y.; Staab, R.; Livingston, Robert B; Valdivieso, M.; Burgess, M. A.; Bodey, G. P.

In: Cancer Treatment Reports, Vol. 62, No. 10, 1978, p. 1603-1605.

Research output: Contribution to journalArticle

@article{ef11d748e6bd433aafc633cb731981fe,
title = "Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: Comparison of oral and continuous iv administration of 5-fluorouracil",
abstract = "Forty-six patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds. The overall response rate in 37 patients with measurable disease was 25{\%}. The response was greater in patients who had had no prior treatment (seven of 20 versus two of 17) and in patients treated with FCC-CIF (six of 19 versus three of 18). Among patients receiving FCC-CIF, response was also greater in those who had received no prior therapy (five of nine versus one of ten). The overall median survival was 7.5 months, regardless of the route of administration of 5-FU. Further investigations are indicated to study the efficacy of 5-FU administered by continuous iv infusion in combination with other agents in patients who have had no prior treatment.",
author = "Bedikian, {A. Y.} and R. Staab and Livingston, {Robert B} and M. Valdivieso and Burgess, {M. A.} and Bodey, {G. P.}",
year = "1978",
language = "English (US)",
volume = "62",
pages = "1603--1605",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU

T2 - Comparison of oral and continuous iv administration of 5-fluorouracil

AU - Bedikian, A. Y.

AU - Staab, R.

AU - Livingston, Robert B

AU - Valdivieso, M.

AU - Burgess, M. A.

AU - Bodey, G. P.

PY - 1978

Y1 - 1978

N2 - Forty-six patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds. The overall response rate in 37 patients with measurable disease was 25%. The response was greater in patients who had had no prior treatment (seven of 20 versus two of 17) and in patients treated with FCC-CIF (six of 19 versus three of 18). Among patients receiving FCC-CIF, response was also greater in those who had received no prior therapy (five of nine versus one of ten). The overall median survival was 7.5 months, regardless of the route of administration of 5-FU. Further investigations are indicated to study the efficacy of 5-FU administered by continuous iv infusion in combination with other agents in patients who have had no prior treatment.

AB - Forty-six patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds. The overall response rate in 37 patients with measurable disease was 25%. The response was greater in patients who had had no prior treatment (seven of 20 versus two of 17) and in patients treated with FCC-CIF (six of 19 versus three of 18). Among patients receiving FCC-CIF, response was also greater in those who had received no prior therapy (five of nine versus one of ten). The overall median survival was 7.5 months, regardless of the route of administration of 5-FU. Further investigations are indicated to study the efficacy of 5-FU administered by continuous iv infusion in combination with other agents in patients who have had no prior treatment.

UR - http://www.scopus.com/inward/record.url?scp=0018215808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018215808&partnerID=8YFLogxK

M3 - Article

C2 - 361230

AN - SCOPUS:0018215808

VL - 62

SP - 1603

EP - 1605

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -